Document is current

Article History

Received: 28 May 2025

Accepted: 10 November 2025

First Online: 11 December 2025

Declarations

:

: The study was performed in accordance with the Declaration of Helsinki and its later amendments. The study procedures were explained to participants verbally and through written informed consent that was approved by the local IRB of each site participating in the GAP consortium (see the Bio-Hermes study website [ ] for a list of study sites). If, in the opinion of the site principal investigator, the participant did not have the capacity to sign the informed consent form, a legally authorized representative was used to grant consent on behalf of the participant.

: Not applicable.

: AJ, KT, CTS, CH, JS, and ST are employees of Linus Health and declare ownership of shares or share options in the company. DB is a co-founder of Linus Health and declares ownership of shares or share options in the company. APL is a co-founder of Linus Health and declares ownership of shares or share options in the company. APL serves as a paid member of the scientific advisory boards for Neuroelectrics, Magstim Inc., TetraNeuron, AscenZion, Bitbrain, Skin2Neuron, and MedRhythms. The authors are listed as inventors on pending patents related to digital biomarkers of cognitive, functional, and amyloid PET status.